Evotec SE 6-K, filed May 6, 2025

Evotec SE (EVO)

6-K 2025-05-06 For: 2025-05-06

View Original

Added on April 06, 2026

About this 6-K

Evotec SE filed this 6-K on May 6, 2025.

Search and read filings like this one from Claude or ChatGPT with the SEC filings MCP server →

Exhibit		Description of Exhibit
99.1		Evotec SE Interim Statement first three months 2025 dated May 6, 2025

	Evotec SE


	By:	/s/ Paul Hitchin
		Name: Paul Hitchin
		Title: Chief Financial Officer

	Three months ended March 31, 2025												Three months ended March 31, 2024
In k€	Shared R&D			Just – Evotec Biologics			Inter- segment Eliminations			Evotec Group			*Shared R&D*			Just – Evotec Biologics			Inter- segment Eliminations			Evotec Group
Revenues¹⁾		140,590			59,389						199,978			155,185			53,542						208,726
Intersegment revenues		2			—			(2	)								268			(268	)
Costs of revenues		(125,381	)		(47,373	)		2			(172,752	)		(135,361	)		(38,806	)		200			(173,967	)
Gross profit		15,211			12,015			—			27,226			19,824			15,004			(68	)		34,760
Gross margin in %		11	%		20	%		—	%		14	%		13	%		28	%		—	%		17	%

R&D expenses		(10,706	)		(52	)		—			(10,758	)		(16,251	)		(59	)		68			(16,242	)
SG&A expenses		(39,341	)		(8,356	)		—			(47,697	)		(38,171	)		(7,766	)		—			(45,937	)
Other operating income		12,312			665			—			12,977			12,165			516			—			12,681
Other operating expense		(904	)		(660	)		—			(1,564	)		(3,469	)		—			—			(3,469	)
Reorganization costs		(192	)		—			—			(192	)		—			—			—			—
Operating income (loss)		(23,620	)		3,611			—			(20,008	)		(25,903	)		7,695			—			(18,207	)

Adjusted EBITDA		(6,856	)		9,964			—			3,107			(5,463	)		13,279						7,815

in k€ except share and per share data	Three months ended March 31, 2025			Three months ended March 31, 2024
Revenue		199,978			208,726
Costs of revenue		(172,752	)		(173,967	)
Gross profit		27,226			34,760

Operating income (expenses)
— Research and development		(10,758	)		(16,242	)
— Selling, general and administrative expenses		(47,697	)		(45,937	)
— Other operating income		12,977			12,681
— Other operating expenses		(1,564	)		(3,469	)
— Reorganization costs		(192	)		—
Total operating income (expenses)		(47,235	)		(52,967	)
Operating income (loss)		(20,008	)		(18,207	)

Non-operating income (expense)
Gain (loss) on investment in financial instruments reevaluation		—			(8,162	)
Share of profit (loss) and reevaluation of at-equity investments		(571	)		(1,051	)
Other financial income		1,216			1,418
Other financial expense		(2,407	)		(2,673	)
Other non-operating income (expense)		(8,082	)		1,894
Total non-operating income (expense)		(9,843	)		(8,574	)

Net Income (loss) before taxes		(29,851	)		(26,782	)
Total taxes		(1,726	)		6,109
Net income (loss)		(31,577	)		(20,673	)

Weighted average shares outstanding		177,526,086			177,301,250
Net result per share		(0.18	)		(0.12	)

in k€	March 31, 2025			December 31, 2024
ASSETS
Current Assets:
— Cash and cash equivalents		285,377			306,387
— Investments		86,066			90,413
— Trade and other receivables		167,280			116,319
— Contract assets		53,931			46,034
— Inventories		33,508			31,122
— Current tax assets		31,564			41,879
— Other current financial assets including derivatives		7,269			4,290
— Prepaid expenses and other current assets		58,883			45,519
Total current assets		723,877			681,964

Non-current assets:
— Non-current investments and other non-current financial assets		40,911			40,014
— Investments in associates and Joint ventures		5,143			2,138
— Property, plant and equipment		808,775			823,937
— Intangible assets and Goodwill		308,282			309,295
— Deferred tax assets		16,364			17,333
— Non-current tax assets		38,598			34,357
— Other non-current assets		2,952			3,464
Total non-current assets		1,221,024			1,230,538
Total assets		1,944,902			1,912,502

LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities
— Current financial liabilities		60,922			50,795
— Trade and other payables		61,299			85,792
— Contract liabilities		125,766			106,599
— Deferred income		3,858			3,216
— Provisions		68,119			62,219
— Current income tax liabilities		9,174			8,517
— Other current liabilities		27,781			27,446
Total current liabilities		356,920			344,585

Non-current liabilities:
— Non-current financial liabilities		417,789			392,743
— Deferred tax liabilities		13,540			14,516
— Provisions		19,753			19,585
— Contract liabilities		194,372			156,679
— Deferred income		29,148			30,557
— Other non-current liabilities		1,239			1,312
Total non-current liabilities		675,841			615,392

Stockholders’ equity:
— Share capital		177,764			177,553
— Additional paid-in capital		1,456,963			1,454,688
— Retained Earnings		(703,947	)		(672,370	)
— Accumulated other comprehensive income		(18,639	)		(7,347	)
Total stockholders' equity		912,141			952,525
Total liabilities and stockholders’ equity		1,944,902			1,912,502

in k€	Three months ended March 31, 2025			Three months ended March 31, 2024
Cash flows from operating activities:
— Net income (loss)		(31,577	)		(20,673	)
— Adjustments to reconcile net income to net cash provided by operating activities		32,971			32,619
— Change in assets and liabilities		(33,201	)		(60,122	)
Net cash provided by (used in) operating activities		(31,808	)		(48,177	)

Cash flow from investing activities:
— Interest Received		1,309			1,072
— Purchase of property, plant and equipment*		(18,198	)		(40,237	)
— Proceeds from sale of property, plant and equipment		98			467
— Purchase of intangible assets and capitalization of development expenditures		(3,640	)		(3,002	)
— Purchase of investments in associated companies and other long-term investments and convertibles		(5,279	)		(5,267	)
— Purchase of current investments		—			(8,000	)
— Proceeds from sale of current investments		4,105			19,994
— Proceeds from government grants*		—			4,066
Net cash used in investing activities		(21,607	)		(30,907	)

Cash flow from financing activities:
— Interest Paid		(1,006	)		(88	)
— Proceeds from loans		43,961			930
— Proceeds from the exercise of share options		210			365
— Repayment of loans		(1,118	)		(966	)
— Repayment of lease obligation		(6,619	)		(6,112	)
Net cash provided by (used in) financing activities		35,429			(5,871	)

Net increase (decrease) in cash and cash equivalents		(17,985	)		(84,955	)
Effects of revaluation and of movements in exchange rates on cash held		(3,024	)		2,358
Cash and cash equivalents at beginning of year		306,387			510,908
Cash and cash equivalents at end of the period		285,377			428,311